BCLI · Brainstorm Cell Therapeutics Inc.
$0.84
-0.33 (-28.21%)
At close · Jul 18
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. Management’s plan includes raising funds from outside potential investors, however, as mentioned above, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives.”View the 10-Q filed Aug 14, 2026
Market Cap
$10.81M
Shares
11.03M
Volume · Jul 18
819.7K
Avg daily vol (3M)
1.39M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.84
Open$0.70
Day$0.59–0.89
52W close$0.76–5.70
Avg vol 30d524K
Short int47K · 0.4% float · 2.5d
Short vol43%
Last earningsNov 14, 2025
DataJan 2020–Jul 2025
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
call held Aug 14, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$10.52M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+28.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−46%
below
Price vs 50-day avg
−28%
below
RSI (14)
29
oversold
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−31%
trailing
6-month return
−62%
trailing
YTD return
−63%
this year
Relative strength
−65%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-86% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.43% of float · ▲ +3.0% MoM · 2.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
5 holders — near 3-yr low, contrarian setup
Fundamentals
EPS growth
+52%
Y/Y
Free cash flow
$-7.0M
Quant / Vol
risk profile
Volatility
101%
annualized · 1-yr
Max drawdown
−87%
past year
ATR
15.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−46%
Bearish
Price vs 50-day avg
−28%
Bearish
RSI (14)
29
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-86% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.43% of float · ▲ +3.0% MoM · 2.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
5 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $1 · 2%
Range high $6
vs 200-day avg -46%
vs 50-day avg -28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCLI
this stock
Brainstorm Cell Therapeutics Inc.
|
$10.81M | — | — | — | 0.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
5
- % held
- 0.0%
- Net QoQ
- -390.5K sh
- Top holder
- OSAIC HOLDINGS, INC.
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCLI | -30.0% | -30.6% | -61.6% | -25.0% | -63.0% |
| SPY | +0.6% | +5.0% | +3.2% | +1.6% | +7.1% |
| vs SPY | -30.6% | -35.6% | -64.9% | -26.6% | -70.1% |